Trialbee announces strong sales results and a 10 yearlong patient engagement and retention assignment

MALMÖ, SWEDEN and RESEARCH TRIANGLE PARK, NC — September 3, 2019 —

Trialbee announces strong sales results in H1 2019 and the launch of a 10 yearlong assignment for its engagement and retention technology with one of the largest global pharmaceutical companies.

Trialbee, a leading technology company in the development of innovative software to reduce clinical trial recruitment timelines and increase the patient engagement experience, announces the appointment of Richard Thomas as its new member to its Board of Directors.

Trialbee delivered strong YoY sales result for its patient matching and engagement technology and exceeded its H1 2019 sales target by 26%. The sales uptake in H1 2019 is predominately driven by growth within the pharmaceutical customer segment. H1 has also demonstrated an increased interest among some of the leading global Contract Research Organizations, a trend the company believes will continue to develop. Sales in H1 is also indicating that customers are requesting to onboard Trialbee’s technology earlier in the drug development process, which is in line with Trialbee’s sales strategy. The technology platform is gaining more momentum as an embedded solution from clinical trial planning through the patient retention phase.

“We are pleased to note that our solutions are delivering demonstrable recruitment and retention efficiencies for our customers, which has advanced Trialbee to become an embedded healthcare partner with major clients, a key strategic driver for continued double digit growth.” Robert Molander, Chief Commercial Officer at Trialbee, said.

In addition to the strong sales result in H1, Trialbee was also successful in landing its longest engagement and retention assignment with one of the largest pharmaceutical companies. Trialbee’s engagement technology will follow more than 3,000 subjects over a 10-year period to support timely and accurate monitoring of questionnaire completeness. The assignment demonstrates the potential of the technology and future applications, but also the high value it delivers to patients and sponsors in securing reliable long-term study outcomes.

About Trialbee:

Trialbee is a world leading technology provider in patient matching and engagement, empowering patients to participate in clinical trials as a care option. Founded in 2010, Trialbee has continuously innovated patient-centric technology solutions for global clinical trials. Trialbee – Dedicated to patients; driven by science; and powered by data. For more information, visit trialbee.com and contact us at [email protected]

 

Press Contact:
Robert Grimm

+46(0)76-525 82 11
[email protected]

Investor Contact:
Daniel Spasic

Executive Chairman Trialbee
[email protected]

Meet us in Milan during OCT Europe 2019, May 14-15

Meet with Trialbee @OCT Europe 2019

Meet us in Milan, Italy, during OCT Europe 2019, May 14-15!

We will be there to share our latest digital solutions and insights within patient recruitment and patient engagement for patient-centric and accelerated clinical research. Please join us during our session on May 15 “Entering the next dimension in clinical trials with digital recruitment and engagement” and come by our booth #58. Contact George Dorsett to book a meeting for the conference.

Read more about OCT Europe

Trialbee Continues to Contribute to Innovation in Diabetes

Trialbee is pleased to announce a new active partnership with the Diabetes Alliance Sweden. Trialbee´s active participation will hopefully act as a catalyst in the formation of new collaborations, securing that important innovations become available to diabetics in Sweden and globally. 

Trialbee Signs Two Top Ten Pharmaceutical Companies for its Patient-Matching and Engagement Platforms

 Trialbee announces two commercial milestones with two of the top 10 pharma companies. Trialbee has been selected to accelerate the clinical development of new drugs through its patient recruitment platform. The two partnerships also include deployment of Trialbee’s engagement application to ensure patient retention and study procedure compliance.

SCOPE Summit 2019

SCOPE Summit 2019

Meet us in Orlando, Florida during SCOPE Summit 2019, on Feb 18-21 where we will share our latest solutions and insights. Please contact Alicia Foley or Joe Buser to book a meeting.

Read more about SCOPE here.

Cookie Preferences

Cloudflare

The Cloudflare cookie is used to identify individual clients behind a shared IP address and apply security settings on a per-client basis.

PHPSESSID,wp-settings-time-1

Google Analytics

Used by Google AdWords to re-engage visitors that are likely to enrol based on the visitor's online behaviour across websites.

_ga,_gid,_gat_UA,_utmc,UULE,CONSENT,1P_JAR,DV

Trialbeehealth

Wordpress built-in cookies to keep user settings after page transitions.

PHPSESSID,wp-settings-time-1

Close your account?

Your account will be closed and all data will be permanently deleted and cannot be recovered. Are you sure?